News AstraZeneca buys cell therapy biotech for up to $1bn AstraZeneca plans to acquire Belgian in vivo cell therapy biotech EsoBiotec and has signed a pair of licensing deals with drug delivery firm Alteogen.
News Taiho snaps up ADC partner Araris for up to $1.14bn Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.
News AbbVie builds the case for ovarian cancer drug Elahere AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.
News Sutro puts lead ADC on hold, cuts staff and changes CEO Sutro has shelved its lead drug for ovarian cancer and turned its attention to three preclinical candidates in a major shake-up of its business.
News Kelun-Biotech first to bag TROP2 approval in lung cancer Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.
News Pfizer's new drug data in breast cancer draws muted response Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.